April 27, 2020 / 10:06 AM / a month ago

BRIEF-Compugen Presents Data Update From Ongoing Phase 1 Trial Of Com701 At The 2020 AACR Virtual Annual Meeting

April 27 (Reuters) - Compugen Ltd:

* COMPUGEN PRESENTS DATA UPDATE FROM ONGOING PHASE 1 TRIAL OF COM701 AT THE 2020 AACR VIRTUAL ANNUAL MEETING

* COMPUGEN LTD - COM701 WAS WELL-TOLERATED WITH NO DOSE-LIMITING TOXICITIES OBSERVED AS A MONOTHERAPY AND IN COMBINATION WITH OPDIVO

* COMPUGEN LTD - ENCOURAGING SIGNALS OF DURABLE DISEASE CONTROL, FROM ONGOING PHASE 1 TRIAL OF COM701 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below